Comprehensive Identification of Cardiovascular Safety Liabilities Using a Totality of Evidence

(58:32)

Cardiovascular Safety of Celecoxib | NEJM

(2:47)

75th Scientific Sessions: Studying Cardiovascular Safety of Type 2 Diabetes Medications

(4:19)

The PRONOUNCE Trial: The Cardiovascular Safety of Degarelix vs. Leuprolide

(4:47)

Dr Daniel Landau Presents CALQUENCE Long-Term and Pooled Cardiovascular Safety Data for CLL/SLL

(27:13)

Cardiovascular Safety for Feboxustat with Dr. Nicola Dalbeth

(4:55)

Cardiac Safety Profile of Vildagliptin 100mg SR- Ft. Prof. Dr Aravinda Jagadeesha- (Part 2)

(1:28)

Study looks at testosterone replacement and its impact on cardiac safety

(1:46)

Research Ins]i[ghts Cardiac Safety Symposium 2021

(6:43:27)

Cardiovascular safety of oral alitretinoin, F. Poizeau et al

(1:46)

Should Diabetes Drugs Require CV Safety Studies Prior to Approval?

(16:)

FDA panels revisit rosiglitazone's cardiovascular safety

(4:19)

Lorcaserin shows cardiovascular safety

(6:34)

Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists

(6:11)

Cardiac Safety Solutions by Harvard Bioscience | Explainer Video

(2:42)

Radiation Safety (Carlos Bechara, MD) Saturday, August 20, 2016

(17:29)

Erenumab in migraine with or without aura: cardiovascular safety

(7:37)

The Findings of the TRAVERSE TRIAL: The Testosterone Cardiovascular Safety Trial

(2:28)

HTS and Cell-Based Phenotypic Screening to Identify Potential Cardiac and Cardiovascular Liabilities

(28:56)

High-throughput screening for in vitro potency evaluation of cardiac ion channel inhibitors on FLIPR

(18:41)